Specialty Pharma Journal Specialty, Precision & Technology
SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. Gamma secretase is an enzyme that cleaves a …
Tag Archives: Fred Hutchinson Cancer Research Center
December, 2017
January, 2017
-
16 January
10x Genomics Announces Publication of Study Demonstrating Single Cell Profiling in Leukemia Patients
PLEASANTON, Calif.–(BUSINESS WIRE)–10x Genomics, Inc., a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced the publication of a study enabled by the company’s Chromium™ Single Cell 3’ Solution. This powerful new technology provides robust single-cell expression measurements, allowing the discovery of gene expression dynamics …
September, 2016
-
9 September
Juno Announces Positive Data for its CAR-T Therapy from Early-Stage NHL Trial
SEATTLE–(BUSINESS WIRE)–Sep. 7, 2016– In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made …
April, 2015
-
22 April
Study Finds CIVO Technology Enables Assessment of Multiple Cancer Drugs and Predicts Response
A microinjection platform enables assessment of multiple cancer drugs directly in tumors and predicts systemic response to the drugs, a new study found. Researchers at Fred Hutchinson Cancer Research Center and Presage Biosciences found that a newly developed technology for simultaneously comparing response to multiple cancer drugs or combinations while …